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Abstract. We investigated the effect of a multidomain lifestyle intervention on the risk of dementia estimated using the
validated CAIDE risk score (post-hoc analysis). The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment
and Disability (FINGER) is a 2-year randomized controlled trial among 1,260 at-risk older adults (60–77 years). Difference
in the estimated mean change in CAIDE score at 2 years in the intervention compared to the control group was –0.16 (95
% CI –0.31 to 0.00) (p = 0.013), corresponding to a relative dementia risk reduction between 6.04–6.50%. This could be
interpreted as a reflection of the prevention potential of the intervention.
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INTRODUCTION
Preventing dementia is a major public health pri-
ority [1]. Early identification of at-risk individuals
is essential for effective preventive strategies. Sev-
eral dementia risk algorithms have been developed
based on various combinations of risk factors, often
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non-modifiable (e.g., age, sex, genetics) [2]. How-
ever, in addition to quantifying dementia risk, it is
important to estimate prevention potential, i.e. the
“room for risk reduction” with preventive interven-
tions. Risk scores including modifiable factors (e.g.,
lifestyle, vascular, or metabolic) may be particularly
useful for this purpose.
The Finnish Geriatric Intervention Study to Pre-
vent Cognitive Impairment and Disability (FINGER)
was the first large, longer-term randomized controlled
trial to report significant benefits on cognition [3],
health-related quality of life [4], disability [5], and
multimorbidity [6] for a 2-year multidomain lifestyle
intervention among 1,260 older individuals with ele-
vated dementia risk. Here we report post-hoc analyses
of intervention effects on change in the Cardiovas-
cular Risk Factors, Aging and Dementia (CAIDE)
Dementia Risk Score. The CAIDE score is a vali-
dated tool for estimating dementia risk based on age,
sex, education, systolic blood pressure, body mass
index, serum total cholesterol, and physical activity
[7, 8], and it was used to select at-risk participants to
the FINGER trial.
METHODS
The FINGER trial (ClinicalTrials.gov NCT
01041989) protocol [9], recruitment [10], and pri-
mary results [3] have been previously reported.
FINGER is a multicenter study conducted in 6 cen-
ters in Finland. It was approved by the Coordinating
Ethics Committee of the Hospital District of Helsinki
and Uusimaa. Participants gave written informed
consent.
Participants were recruited from previous pop-
ulation-based observational studies [10]. Eligibility
criteria were: age 60–77 years; CAIDE Dementia
Risk Score ≥ 6 points (for screening purpose calcu-
lated based on data from previous surveys, up to 40
years before the trial); and at least one cognitive test
criterion: the Consortium to Establish a Registry for
Alzheimer’s Disease (CERAD) [11, 12] Word List
Memory task (10 words x3) ≤19 words, or CERAD
Word List Recall ≤ 75%, or Mini-Mental State
Examination (MMSE) [13] ≤ 26/30 points. Exclu-
sion criteria were: dementia; MMSE < 20 points;
conditions affecting safe participation or preventing
co-operation; and coincident participation in another
trial.
Between September 7, 2009 and November 24,
2011, 2,654 individuals were screened for eligibility,
and 1,260 were randomized 1:1 into the intensive
multidomain intervention or regular health advice
(i.e., control) group. Computer-generated random-
ization was done in blocks of four individuals at
each site. Outcome assessors were blinded to allo-
cation and not involved in the intervention. The
control group received regular health advice. The
intervention group received nutritional advice (indi-
vidual and group sessions led by study nutritionists),
physical exercise program supervised by study phys-
iotherapists at the gym, cognitive training (individual
computer-based training, and group sessions led by
study psychologists), and management of metabolic
and vascular risk factors [9]. The intervention was
completed in February 2014.
Risk factors included in the CAIDE score are
based on data from population register (age, sex),
self-reported questionnaires (education, physical
activity), measurements by the study nurse (systolic
blood pressure, body mass index), and laboratory
analyses (serum total cholesterol).The scoring sys-
tem has been reported and validated previously [7,
8]. CAIDE Dementia Risk Score was calculated using
data from the FINGER baseline, 12- and 24-month
visits. In addition, APOE  genotype was assessed
[14]. T-test or χ2 test was used for baseline compar-
isons between intervention and control groups. Mixed
effects regression models with maximum likelihood
estimation were used to analyze change in CAIDE
score as a function of randomization group, time,
and group x time interaction. All participants with
CAIDE score available from at least one time point
were included in the main analysis (intention-to-treat)
(n = 1,254, 99.5%). Sensitivity analyses were con-
ducted including only participants with CAIDE score
data at all time points (n = 1,030). Potential effect
modification by other variables (baseline age, con-
tinuous; sex; or presence of at least one APOE 4
allele) was investigated by adding the group x time
x variable interaction to the model, together with the
main variable effect and variable x time and variable
x group interactions.
Analyses were adjusted by study site. Level of
significance was set to p = 0.05 in all analyses; we
also report three-way interactions with p < 0.10. Stata
software version 14 was used.
RESULTS
Intervention and control groups were not signifi-
cantly different in sociodemographic characteristics,
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Table 1
Baseline characteristics
Number of Intervention Control group p
participants group (N = 631) (N = 629)
Age at baseline, y 1260 69.5 (4.7) 69.2 (4.7) 0.26
Women, N (%) 1260 286 (45.3) 302 (48.0) 0.34
Education, y 1258 10.0 (3.5) 10.0 (3.4) 0.94
Body mass index 1251 28.3 (4.5) 28.1 (4.9) 0.44
Systolic blood pressure, mmHg 1251 140.2 (16.6) 140.0 (15.7) 0.77
Physical inactivity, N (%) 1247 189 (30.2) 175 (28.1) 0.41
APOE4 carrier, N (%) 1175 189 (32.0) 200 (34.2) 0.43
Baseline CAIDE score 1233 7.9 (1.8) 7.8 (1.9) 0.69
Values are mean (SD) or N (%). The CAIDE Dementia Risk Score was calculated based on a combination of age, sex, education, systolic
blood pressure, body mass index, total cholesterol and physical activity, as previously described [7].
vascular and lifestyle factors, medical history, cog-
nitive performance (as previously described [3]), or
CAIDE score (Table 1) at baseline. 1,254 (99.5%)
participants had CAIDE score data from at least one
trial visit.
The estimated mean change in CAIDE score in
the intervention and control group during the trial is
shown in Fig. 1. Between-group difference was sig-
nificant (p = 0.013 for the group×time interaction).
Estimated mean change in CAIDE score at 2 years
was –0.15 (95% CI –0.26 to –0.04) in the control and
–0.31 (95% CI –0.42 to –0.20) in the intervention
group, with between-group difference –0.16 (95% CI
–0.31 to 0.00). The estimated between group differ-
ence in mean change in CAIDE score at year 1 was
–0.22 (95% CI –0.37 to –0.07). Results remained
unchanged in sensitivity analysis (participants with
CAIDE score data at all 3 time points).
Fig. 1. Change in CAIDE Dementia Risk Score during the 2-year
intervention. The figure shows estimated means of CAIDE score
at baseline, 12 and 24 months (lower scores indicate lower risk for
dementia). Error bars are CIs. Mixed-model repeated-measures
analysis was used to assess between-group differences (random-
ization group×time interaction) in change from baseline to 24
months.
The intervention benefit on CAIDE score change
tended to be more pronounced among women than
men (p = 0.098 for the randomization group x time
x sex interaction). The 2-year estimated between-
group difference for men was –0.03 (95% CI –0.24 to
0.19) and for women –0.31 (95% CI –0.54 to –0.08).
There were no differences in attrition between men
and women.
No significant differences were found by age or
APOE 4 carrier status (p > 0.32).
To translate the intervention-related change in
CAIDE score into estimates of dementia risk reduc-
tion, we used a previously reported formula for
calculating 20-year dementia risk in middle-aged
individuals [7]:
P (dementia) = e
(−7.406 + 0.796 + 0.401 ∗ SCORE)
1 + e(−7.406 + 0.796 + 0.401 ∗ SCORE)
where SCOREcontrol was the baseline CAIDE score
(mean 7.86 for all participants) minus 1 point
for age to reflect a middle-aged population; and
SCOREintervention was SCOREcontrol minus 0.16 (esti-
mated 2-year intervention-related decrease in CAIDE
score). With a control group 20-year risk of 2.07%,
and an intervention group risk of 1.94%, their ratio
was 0.94. This indicated a relative risk reduction of
6.09%. Without the age adjustment, the relative risk
reduction was 6.04%. Similar calculations using the
observed 2-year difference in CAIDE score change
between intervention and control groups (–0.17) with
and without age adjustment resulted in a relative risk
reduction between 6.44% and 6.50%.
DISCUSSION
In the FINGER trial, there was a significant
beneficial intervention effect on reducing estimated
dementia risk measured by the CAIDE score. This
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effect tended to be more pronounced in women. As
the intervention was more intensive during the first
year, the reduction in CAIDE score was also more
pronounced during the first year followed by main-
tenance of the risk score reduction during the second
year.
These post-hoc analyses could be interpreted as
a reflection of the prevention potential of the inter-
vention. The FINGER intervention was started early,
in at-risk individuals without substantial cognitive
impairment [3], and therefore incident dementia was
not a feasible outcome after 2 years. For several rea-
sons, the estimates presented here may not reflect
the actual magnitude of dementia risk reduction:
The CAIDE Dementia Risk Score is based on sim-
ple cut-offs for risk factors, restricting its sensitivity
to change over time. While it also includes non-
modifiable risk factors, the intervention effect is less
likely to be overestimated since risk estimates are
adjusted for such factors. Also, the CAIDE score
was developed as the first midlife risk score for esti-
mating dementia risk 20 years later and was used
to select FINGER participants based on pre-trial
midlife data. In addition, the FINGER control group
received a program of regular general health advice
as per national guidelines, leading to more conserva-
tive intervention effect estimates than a “do-nothing”
control group. Although the CAIDE score was also
reduced in the control group (a benefit that may at
least partly be explained by “trial effect”, regression
to the mean or other factors) [15, 16], the reduction
was significantly greater in the intervention group.
The intervention effect on the CAIDE score tended
to be more pronounced among women, although the
test of interaction was not significant. Given the lim-
ited sample size it is not possible to provide reliable
estimates separately for men and women. Hopefully
larger trials and joint analyses across multidomain
lifestyle trials will allow more detailed subgroup
analyses in the future, including analyses of sex dif-
ferences in intervention efficacy and adherence.
We based our estimates of change in dementia risk
on data from the middle-aged observational cohort
originally used to develop the CAIDE score [7].
This is because dementia risk estimates in observa-
tional studies of older populations may be influenced
by reverse causation, i.e., vascular/metabolic factors
may be affected by “silent” disease processes. How-
ever, because the CAIDE risk score was developed
and validated in a midlife population, the estimated
risk of dementia is most likely an underestimation
in this population of older adults. Ongoing FINGER
extended follow-up will provide data on observed
dementia incidence, and more accurate risk reduc-
tion estimates and evaluation of the CAIDE score
as a potential surrogate outcome in lifestyle-based
dementia prevention trials [17].
As FINGER targeted at-risk participants from the
general population, the importance of potential risk
reduction should be interpreted in a public health
context. There is currently no direct evidence of cost-
efficacy of dementia prevention interventions, but
previous modelling studies have suggested that rela-
tively small risk reductions (0.6–3.2%) may already
be cost-effective [18].
The FINGER participants were recruited from
previous population-based studies and they are well-
representative of at-risk older adults in Finland [10].
The CAIDE score has been validated in, e.g., diverse
population in the US, and therefore also our results
may be at least to some extent generalizable to
other older at-risk populations. However, the rela-
tive importance of modifiable risk factors may differ
across populations and over time. In an early preven-
tion trial it is still difficult to estimate the potential
clinical significance of the findings. CAIDE risk score
can be used as a tool to communicate dementia risk,
and to select persons that may benefit from lifestyle
interventions. Based on the current results, it can per-
haps also be used to track risk factor changes. Novel
biomarker assays as well as additional lifestyle and
clinical measures may contribute to further develop-
ment of more sensitive risk scores.
In conclusion, an important area for future develop-
ments in dementia prevention would be multifactorial
algorithms that estimate both dementia risk and pre-
vention potential and are highly sensitive to capturing
change in various risk factors over time. Establish-
ing risk models as surrogate outcomes for dementia
development would greatly facilitate assessing the
long-term impact of dementia prevention trials.
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